HB 661

85(R) - 2017

Vote Recommendation

  • Positive
  • Neutral
  • Neutral
  • Positive
  • Positive


Tan Parker

Bill Caption

Relating to access to certain investigational drugs, biological products, and devices that are in clinical trials by patients with severe chronic diseases. 

Fiscal Notes

From the LBB: No significant fiscal implication to the State is anticipated. 

Bill Analysis

Under current law, only patients with terminal illnesses are eligible to access investigational drugs, devices, or biological products in clinical trials. This bill would make patients with severe chronic diseases also eligible to try experimental drugs with informed consent and without interference from the state. This bill clarifies that it would not create a cause of action, and that action against physician's licenses is prohibited as long as the physician's recommendations meet the medical standard of care. 

Vote Recommendation Notes

This bill represents a deregulation of the healthcare market that would help many people with chronic illnesses get access to drugs and therapies that could greatly help them without interference from the government, therefore, we support this bill.